Zoledronic and Multiple sclerosis - a phase IV clinical study of FDA data

Summary:

Multiple sclerosis is reported as a side effect among people who take Zoledronic (zoledronic acid), especially for people who are male, 60+ old, have been taking the drug for 2 - 5 years also take Fulvestrant, and have Osteoporosis.

The phase IV clinical study analyzes which people have Multiple sclerosis when taking Zoledronic. It is created by eHealthMe based on reports of 29,760 people who have side effects when taking Zoledronic from the FDA, and is updated regularly.

What is Zoledronic?

Zoledronic has active ingredients of zoledronic acid. eHealthMe is studying from 29,812 Zoledronic users. Check the latest studies of Zoledronic.

What is Multiple sclerosis?

Multiple sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath) is found to be associated with 1,103 drugs and 1,356 conditions by eHealthMe. Check the latest studies of Multiple sclerosis.

On Apr, 18, 2026

29,760 people reported to have side effects when taking Zoledronic.
Among them, 10 people (0.03%) have Multiple sclerosis.

Could Zoledronic cause Multiple sclerosis?

Among these 10 people:

How long have people been on Zoledronic when they have Multiple sclerosis? *

What is the gender of people who have Multiple sclerosis when taking Zoledronic? *

female: 33.33 %
male: 66.67 %

What is the age of people who have Multiple sclerosis when taking Zoledronic? *

What are other drugs people take besides Zoledronic? *

Sulfamethoxazole And Trimethoprim: 1 person, 10.00%
Ribociclib: 1 person, 10.00%
Prednisone: 1 person, 10.00%
Palbociclib: 1 person, 10.00%
Methotrexate: 1 person, 10.00%
Leuprolide Acetate: 1 person, 10.00%
Letrozole: 1 person, 10.00%
Isoniazid: 1 person, 10.00%
Humira: 1 person, 10.00%
Fulvestrant: 1 person, 10.00%

What are other side effects people have besides Multiple sclerosis? *

Vasogenic Cerebral Oedema (increase in brain water): 1 person, 10.00%
Hyperkalemia (damage to or disease of the kidney): 1 person, 10.00%
Bedridden: 1 person, 10.00%
Bone Density Decreased: 1 person, 10.00%
Bone Disorder: 1 person, 10.00%
Bone Lesion (bone with abnormalities. bone lesions can result from growth formations, infections, or injuries): 1 person, 10.00%
Breast Cancer: 1 person, 10.00%
Breast Lump (localized swelling that feels different from the surrounding breast tissue): 1 person, 10.00%
Cerebral Infarction (less blood supply to brain resulting tissue damage): 1 person, 10.00%
Demyelination (loss of the myelin covering of some nerve fibres resulting in their impaired function): 1 person, 10.00%

What are the existing conditions these people have? *

Osteoporosis (bones weak and more likely to break): 2 people, 20.00%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 1 person, 10.00%
Pneumonia: 1 person, 10.00%
Breast Cancer Metastatic: 1 person, 10.00%
Adverse Event: 1 person, 10.00%
Adverse Drug Reaction: 1 person, 10.00%
Acute Kidney Failure: 1 person, 10.00%

* Approximation only. Some reports may have incomplete information.

Do you take Zoledronic and have Multiple sclerosis?

- Check whether Multiple sclerosis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Zoledronic:

Zoledronic (29,812 reports)

Browse all side effects of Zoledronic:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Multiple sclerosis:

Multiple sclerosis (1,103 drugs)

Browse all the conditions that are associated with Multiple sclerosis:

Multiple sclerosis (1,356 conditions)

Related publications that referenced our studies

Christopher KL, Elner VM, Demirci H, "Conjunctival Lymphoma in a Patient on Fingolimod for Relapsing-Remitting Multiple Sclerosis", Ophthalmic Plastic & Reconstructive Surgery, 2017 May .
Christopher, K. L., Elner, V. M., & Demirci, H. , "Conjunctival lymphoma in a patient on fingolimod for relapsing-remitting multiple sclerosis", Ophthalmic plastic and reconstructive surgery , 2014 Jan .
Christopher KL, Elner VM, Demirci H, "Conjunctival Lymphoma in a Patient on Fingolimod for Relapsing-Remitting Multiple Sclerosis", Ophthalmic Plastic & Reconstructive Surgery, 2017 May .
Christopher, K. L., Elner, V. M., & Demirci, H. , "Conjunctival lymphoma in a patient on fingolimod for relapsing-remitting multiple sclerosis", Ophthalmic plastic and reconstructive surgery , 2014 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on zoledronic acid (the active ingredients of Zoledronic) and Zoledronic (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.